← 治験一覧に戻る
APOLLO：トランスサイレチン（TTR）介在性アミロイドーシスの治療薬パチシラン（ALN-TTR02）の研究
基本情報
- NCT ID
- NCT01960348
- ステータス
- 完了
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 225
- 治験依頼者名
- Alnylam Pharmaceuticals
概要
The purpose of this study is to evaluate the safety and efficacy of patisiran (ALN-TTR02) in patients with transthyretin (TTR) mediated amyloidosis. An open-label, single-arm, long-term follow-up extension study NCT02510261 (ALN-TTR02-006) was initiated to provide participants who completed this study with continued patisiran-LNP (lipid nanoparticle) treatment.
対象疾患
TTR-mediated AmyloidosisAmyloidosis, HereditaryAmyloid Neuropathies, FamilialFamilial Amyloid PolyneuropathiesAmyloid NeuropathiesAmyloidosis, Hereditary, Transthyretin-Related
介入
patisiran (ALN-TTR02)(DRUG)
Sterile Normal Saline (0.9% NaCl)(DRUG)
依頼者（Sponsor）
Alnylam(INDUSTRY)